Àü¸³¼± ºñ´ëÁõ ±³°ú¼
- ÀúÀÚ(±Û)
- ÃâÆÇ»çÀÏÁ¶°¢
- ¹ßÇàÀÏ2005³â
Àü¸³¼±¾Ï ¡¤ Àü¸³¼± Áúȯ ÇØ°á, ÃֽŠ·Îº¿ ¡¤ º¹°°æ ¼ö¼ú ±ÇÀ§ÀÚ
| Á¦ ¸ñ | ¾Ë±â ½±°Ô ¾´ Àü¸³¼± Áúȯ |
|---|---|
| ÃâÆÇ»ç | ÀÇÇй®È»ç |
| ¹ßÇàÀÏ | 2006³â |
| Á¦ ¸ñ | ¹æ±¤¾Ï Áø·áÁöħ |
|---|---|
| ÃâÆÇ»ç | ÀÇÇй®È»ç |
| ¹ßÇàÀÏ | 2005³â |
| Á¦ ¸ñ | Risk Factors for Sepsis after Retrograde Intrarenal Surgery: Single Center Experience |
|---|---|
| ¹ßÇ¥³âµµ | 2023 |
| ¹ßÇ¥Áö | Urogenital Tract Infection |
| Á¦ ¸ñ | Aggressive Paraganglioma of the Urinary Bladder with Local Recurrence and Pelvic Metastasis |
|---|---|
| ¹ßÇ¥³âµµ | 2020 |
| ¹ßÇ¥Áö | PATHOLOGY & ONCOLOGY RESEARCH |
| Á¦ ¸ñ | Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey |
|---|---|
| ¹ßÇ¥³âµµ | 2019 |
| ¹ßÇ¥Áö | International Journal of Urology |
| Á¦ ¸ñ | Is Double J Stenting or Percutaneous Nephrostomy More Suitable for Maximizing the Clinical Effects of Temporary Urinary Diversion for Acute Pyelonephritis with a Complicated Ureteral Stone? |
|---|---|
| ¹ßÇ¥³âµµ | 2019 |
| ¹ßÇ¥Áö | Urogenital Tract Infection. |
| Á¦ ¸ñ | Blood culture for complicated acute pyelonephritis with ureteral stone: are they unnecessary? |
|---|---|
| ¹ßÇ¥³âµµ | 2018 |
| ¹ßÇ¥Áö | Infectious Diseases. |
| Á¦ ¸ñ | Prognostic Significance of Immunohistochemical MSH2 Expression in Prostate Cancer |
|---|---|
| ¹ßÇ¥³âµµ | 2018 |
| ¹ßÇ¥Áö | ´ëÇѺñ´¢±âÁ¾¾çÇмúÁö |
| Á¦ ¸ñ | Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer: implications for better risk stratification and preoperative prediction of oncologic outcomes |
|---|---|
| ¹ßÇ¥³âµµ | 2017 |
| ¹ßÇ¥Áö | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
Àü¸³¼± ¾ÏÀÇ Á¶±âÁø´Ü ¹× ÀûÁ¤Ä¡·á¸¦ ÅëÇØ »ý¸íÀÇ ¿¬ÀåÀÌ ÁÖ °ü½É»ç·Î ±¹³» ÃÖÃÊ·Î Àü¸³¼±¾Ï ÀÇ½É È¯ÀÚ »ý°ËÈÄ ´çÀÏ·Î °á°ú¸¦ µµÃâÇÏ¿© ȯÀÚÀÇ ½É¸®Àû ¾ÈÁ¤°ú ºü¸¥ ÈÄ¼Ó Ä¡·áÀÇ ¹ßÆÇÀ» ¸¶·ÃÇÏ´Â ½Ã½ºÅÛ ¸¶·Ã
ȯÀÚÀÔÀå¿¡¼ ÁúȯÀ» ¹Ù¶óº¸¸ç ÀÇ»ç¿Í ȯÀÚ°£ÀÇ ÃæºÐÇÑ °ø°¨´ë ¹× °¨Á¤ÀÇ ¼ÒÅëÀ» ÅëÇØ ½Å·Ú¸¦ ¹ÙÅÁÀ¸·Î Á¾¾çÀ» À̰ܳª°¡´Â ÀÇ»ç, ȯÀÚÀÇ ¿øÆÀ ±¸¼º
¸¹Àº ºñ´¢±âÁúȯÀÌ ³ëÈ¿Í ´õºÒ¾î ³ªÅ¸³²À¸·Î ±ä È£ÈíÀ¸·Î Æò¾ÈÇÑ Åµµ·Î Áúº´ ¹× ³ëÈ¿Í ´ëÈÇÑ´Ù´Â »ý°¢À¸·Î ¸ðµç ºñ´¢±âÁúȯÀ» ´ëÇϸé ÈξÀ ÁÁÀº Á¤½ÅÀû À°Ã¼Àû °á°ú·Î µ¹¾Æ¿É´Ï´Ù.

°µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀǷἺñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î Æ¯ÈµÈ ÇùÁø ÀÇ·á
¼ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀǷἺñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.
¼¿ïƯº°½Ã °µ¿±¸ µ¿³²·Î 892